Cellectis S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated April 4, 2023, reports on a material financing update for Cellectis S.A., a biopharmaceutical company based in Paris, France. The filing details the execution of a Subscription Agreement for Warrants with the European Investment Bank (EIB) and the subsequent drawdown of the first tranche of a Finance Contract.
Key Financial Metrics and Capital Structure
- Debt Financing: The Company drew down Tranche A of the Finance Contract in the amount of €20 million, expected to be disbursed in early April 2023.
- Interest Terms: Tranche A matures six years from the disbursement date. Interest accrues at 8.0% per annum and is paid in kind (capitalized annually).
- Equity Issuance: On March 28, 2023, the Company issued 2,799,188 warrants to the EIB (Tranche A Warrants), representing 5.0% of the Company's outstanding share capital at issuance.
- Warrant Exercise Price: The exercise price is set at €1.92 per share (99% of the weighted average price over the last 3 trading days prior to issuance).
- Future Tranches: The Finance Contract includes potential future tranches: Tranche B (€15.0 million) and Tranche C (€5.0 million), subject to specific conditions and warrant issuances.
Material Changes and Contractual Terms
The filing outlines significant covenants and conditions attached to the EIB financing:
- Prepayment Events: Mandatory prepayment may be triggered by a reduction in R&D costs causing the loan to exceed specified percentages of total R&D costs, voluntary prepayment of other indebtedness, change of control, or changes in law rendering performance unlawful.
- Prepayment Fees: Voluntary prepayments within the first three years are subject to a low single-digit percentage fee that steps down annually.
- Warrant Exercisability: Warrants become exercisable upon the earliest of a change of control, maturity of Tranche A, public takeover, asset sale, debt repayment event (mandatory repayment or voluntary payment of >75% of a tranche), or an event of default.
- Put Option: Following an Exercise Event, the EIB may exercise a put option to request the Company repurchase warrants at fair market value, capped at the aggregate principal amount disbursed.
- Restrictions: The agreement includes negative covenants restricting asset dispositions and specified payments such as dividends, share repurchases, and loan repayments to other parties.
Outlook, Risks, and Contingencies
The Company has satisfied the conditions precedent for Tranche A, including the issuance of warrants and the achievement of a specified clinical milestone by a licensee. The filing highlights risks related to events of default, which include payment defaults, cross-defaults with other obligations, material adverse changes, and insolvency. In the event of default, the EIB may demand immediate repayment of all outstanding funds plus accrued interest.
Key Facts for Investor Verification
- Verify the actual disbursement date of the €20 million Tranche A and the impact on the Company's cash position.
- Monitor the Company's R&D spending to ensure it does not trigger the mandatory prepayment clause related to the ratio of the loan to total R&D costs.
- Track the Company's share price relative to the €1.92 warrant exercise price to assess potential dilution upon warrant exercise.
- Review the Company's ability to meet the cash injection thresholds required to unlock Tranche B (€15 million) and Tranche C (€5 million).
- Assess the impact of the 8.0% capitalized interest on the total debt burden over the six-year maturity period.